Transforming asthma care: improving patient and environmental outcomes (Promotional content from AstraZeneca)

Transforming asthma care: improving patient and environmental outcomes (Promotional content from AstraZeneca) | GPnotebook TV

This promotional video has been initiated, created, funded and reviewed by AstraZeneca. This promotional video page is intended for UK Healthcare Professionals only and AstraZeneca products will be discussed. The content has been reviewed and approved by the sponsoring company AstraZeneca and the speakers. Editorial support for this video has been provided by OmniaMed Communications. GPnotebook has had no input into the content.

SYMBICORT® (BUDESONIDE/FORMOTEROL FUMARATE DIHYDRATE) PRESCRIBING INFORMATION
BRICANYL® (TERBUTALINE SULFATE) PRESCRIBING INFORMATION
OXIS® (FORMOTEROL FUMARATE DIHYDRATE) PRESCRIBING INFORMATION
PULMICORT® (BUDESONIDE) PRESCRIBING INFORMATION

Please note: Symbicort (budesonide/formoterol) Turbohaler 100/6, 200/6 are licensed for Maintenance And Reliever Therapy (MART)^1,2

Symbicort Turbohaler 400/12 is licensed for Maintenance Therapy only³

Transforming asthma care: improving patient and environmental outcomes (Promotional content from AstraZeneca)

17 August 2022

Sponsored

A plethora of national and international guidelines exist for the management of asthma; how can healthcare professionals best make sense of these different sources of advice, in order to develop a management plan that best suits the needs of the patient in front of them? Not only must the patient’s individual clinical characteristics, preferences and lifestyle factors be taken into consideration, but also national clinical priorities such as the NHS sustainability agenda. This video offers an evidence-based approach to individualising asthma management.

Symbicort Turbohaler licensed indication

Symbicort® Turbohaler is indicated for adults, adolescents 12 years and older and children aged 6 years and older (100/6 Turbohaler for maintenance therapy only) for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonists) is appropriate:

– Patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists

– Patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists

Symbicort Turbohaler 400/12 should be used as Maintenance Therapy only. Lower strengths are available for the Symbicort Maintenance and Reliever Therapy regimen (100mcg/6mcg/inhalation Turbohaler, 200mcg/6mcg/inhalation Turbohaler).

References

SYMBICORT (budesonide/formoterol) Turbohaler 100/6, Inhalation powder. Summary of Product Characteristics
SYMBICORT (budesonide/formoterol) Turbohaler 200/6, Inhalation powder. Summary of Product Characteristics
SYMBICORT (budesonide/formoterol) Turbohaler 400/12, Inhalation powder. Summary of Product Characteristics

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.

GB-38224 | August 2022

Transforming asthma care: improving patient and environmental outcomes (Promotional content from AstraZeneca)

Related video

GB-38229 | August 2022

This account does not have a GPnotebook Pro registration

Congratulations!

Log in to track your activity and claim CPD credits

Already registered for GPnotebook Pro?

Not yet registered for GPnotebook Pro?